Eagle Competitors

Delisted . USA . 
Stock . Eagle Pharmaceuticals
EGRXDelisted Stock  USD 1.99  0.02  1.02%   
Eagle Pharmaceuticals competes with ANI Pharmaceuticals, Phibro Animal, Prestige Brand, Collegium Pharmaceutical, and Regencell Bioscience; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Eagle Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Eagle Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Eagle Pharmaceuticals competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.101.9910.63
Details
Intrinsic
Valuation
LowRealHigh
0.091.8910.53
Details
Naive
Forecast
LowNextHigh
0.041.9610.60
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.373.825.28
Details

Eagle Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Eagle Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Eagle and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Eagle Pharmaceuticals does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
SSIC
+ 0.84
PBH
EOLS
+ 0.78
COLL
PBH
+ 0.45
PAHC
EOLS
+ 0.45
AMPH
ALKS
+ 0.42
SSIC
RGC
+ 0.39
ANIP
  
High negative correlations   
EOLS
- 0.91
SSIC
EOLS
- 0.84
PBH
COLL
- 0.83
PBH
SSIC
- 0.73
COLL
COLL
- 0.48
PAHC
AMPH
- 0.46
SSIC

Risk-Adjusted Indicators

There is a big difference between Eagle Pink Sheet performing well and Eagle Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Eagle Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ANIP  1.85 (0.25) 0.00 (0.10) 0.00 
 0.00 
 3.70 
(3.75)
 10.82 
PAHC  2.00  0.24  0.16  0.24  1.63 
(2.32)
 5.36 
(2.45)
 15.47 
DCPH  1.66 (0.22) 0.00 (1.14) 0.00 
 0.00 
 3.27 
(3.25)
 9.66 
PBH  0.92  0.20  0.14  0.37  0.91 
(1.02)
 1.90 
(1.76)
 4.90 
COLL  1.88 (0.34) 0.00 (0.19) 0.00 
 0.00 
 3.59 
(4.47)
 12.29 
SSIC  1.09  0.12  0.04  0.43  1.04 
(1.35)
 2.89 
(1.82)
 7.09 
RGC  6.25 (0.02) 0.00  0.12  0.00 
 0.00 
 22.58 
(10.93)
 43.32 
AMPH  1.58 (0.09) 0.00 (0.10) 0.00 
 0.00 
 3.37 
(3.61)
 17.30 
ALKS  1.71 (0.18) 0.00 (0.01) 0.00 
 0.00 
 4.14 
(3.59)
 9.74 
EOLS  2.40 (0.34) 0.00 (0.22) 0.00 
 0.00 
 4.49 
(4.70)
 22.78 
All Fundamental Data

Eagle Pharmaceuticals Competitive Analysis

The better you understand Eagle Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Eagle Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Eagle Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
EGRX ANIP PAHC DCPH PBH COLL SSIC RGC AMPH ALKS
 1.02 
 1.99 
Eagle
 1.38 
 55.86 
ANI
 1.58 
 23.76 
Phibro
 2.63 
 13.32 
Deciphera
 1.78 
 84.14 
Prestige
 1.37 
 30.41 
Collegium
 1.22 
 12.96 
Silver
 0.88 
 5.65 
Regencell
 1.08 
 44.09 
Amphastar
 0.75 
 27.70 
Alkermes
Market Volatility
(90 Days Market Risk)
Extremely Dangerous
Very steady
Not too volatile
Very steady
Very steady
Very steady
Not too volatile
Very risky
Very steady
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
OK
Very Weak
Good
Very Weak
Good
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Low
Low
Dangerous
Low
Low
Dangerous
About Average
Low
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Over Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Buy
Hold
Not Available
Strong Buy
Buy
Not Available
Not Available
Buy
Buy
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Hold
Strong Hold
Not Rated
Strong Buy
Strong Buy
Not Rated
Strong Sell
Cautious Hold
Hold
Current Ratio
1.78
3.35
2.97
6.02
2.09
0.99
111.63
13.94
3.64
2.38
Net Asset
406.16 M
904.42 M
982.18 M
473.57 M
3.32 B
1.14 B
88.58 M
8.44 M
1.51 B
2.14 B
Profit Margin
0.0464
-0.0128
0.0166
-1.09
0.19
0.15
0.45
N/A
0.22
0.22
EBITDA
65.48 M
109.32 M
84.61 M
(210.96 M)
373.1 M
308.33 M
7.34 M
(3.62 M)
241.46 M
495.05 M
Operating Margin
0.16
-0.0734
0.0811
-1.09
0.3
0.35
0.67
N/A
0.3
0.28
Current Valuation
82.05 M
1.66 B
1.37 B
1.97 B
5.09 B
1.74 B
32.12 M
65.65 M
2.52 B
3.97 B
Price To Book
0.1
2.85
3.66
7.0
2.36
4.19
0.78
8.95
2.94
3.5
Retained Earnings
111.5 M
(80.13 M)
243.89 M
(1.43 B)
1.34 B
(233.19 M)
449.27 K
(21.62 M)
409.27 M
(1.34 B)
Current Asset
119.05 M
192.58 M
342.83 M
70.55 M
249.01 M
96.88 M
N/A
438.2 M
175.93 M
754.96 M
Five Year Return
N/A
N/A
1.85
N/A
N/A
N/A
N/A
4.37
N/A
N/A
Beta
0.52
0.71
0.51
0.18
0.47
0.95
0.28
-0.6
0.82
0.44
Number Of Employees
134
642
1.94 K
355
570
197
5
12
1.76 K
2.1 K
Shares Outstanding
12.96 M
21.02 M
20.34 M
86.48 M
49.41 M
32.25 M
6.21 M
13.01 M
48.08 M
161.8 M
Cash Flow From Operations
30.8 M
118.96 M
87.59 M
(146.7 M)
248.93 M
274.75 M
7.98 M
(4 M)
183.5 M
401.35 M
Annual Yield
N/A
N/A
0.0205
N/A
N/A
N/A
0.094
N/A
N/A
N/A
Total Debt
62.47 M
285.67 M
525.46 M
25.88 M
1.14 B
674.28 M
3.01 M
85.74 K
623.64 M
372.19 M
Return On Equity
0.0488
-0.016
0.0655
-0.5
0.13
0.43
0.0641
-0.43
0.24
0.29
Z Score
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
0.0663
0.0125
0.0526
-0.27
0.0612
0.0968
0.0562
-0.28
0.0867
0.0898
Number Of Shares Shorted
350.53 K
2.16 M
404.72 K
3.92 M
2.37 M
6.21 M
9.78 K
62.16 K
4.34 M
16.12 M
Book Value Per Share
19.25
20.74
6.38
3.85
35.03
7.27
13.56
0.63
15.04
7.99
Current Liabilities
35.45 M
11.76 M
108.78 M
5.98 M
106.68 M
8.43 M
N/A
551.3 M
59.95 M
236.21 M
Total Asset
406.16 M
904.42 M
982.18 M
473.57 M
3.32 B
1.14 B
88.58 M
8.44 M
1.51 B
2.14 B
Debt To Equity
0.23
0.86
1.79
0.075
0.95
3.82
N/A
0.069
0.21
0.38
Short Ratio
3.91
11.73
2.28
1.05
10.3
18.07
4.63
0.31
15.91
8.97
Target Price
17.0
78.4
18.4
27.52
85.29
42.25
8.8
N/A
59.0
34.08
Last Dividend Paid
N/A
N/A
0.48
N/A
N/A
N/A
0.98
N/A
N/A
N/A
Shares Owned By Institutions
76.65
99.57
99.43
72.03
98.7
98.36
76.19
0.19
74.7
98.69
Market Capitalization
27.73 M
1.17 B
962.37 M
2.21 B
4.16 B
980.73 M
66.13 M
73.52 M
2.14 B
4.48 B
Price To Earning
40.52
43.35
11.39
-6.78
18.23
28.8
N/A
26.21
972.67
-38.45
Price To Earnings To Growth
0.91
1.06
1.66
-0.32
2.72
N/A
N/A
2.15
2.77
-1057.29
Price To Sales
0.11
2.11
0.92
12.65
3.74
1.64
5.32
N/A
2.96
2.98
Net Income
(2.67 M)
18.78 M
2.42 M
(194.94 M)
209.34 M
48.16 M
7.34 M
(4.36 M)
137.54 M
355.76 M
Earnings Per Share
0.85
-0.47
0.43
-2.21
4.1
2.34
0.9
-0.33
3.01
2.29
Shares Owned By Insiders
12.02
11.1
0.57
28.48
1.3
1.64
0.43
88.81
22.4
1.31
Revenue
316.61 M
486.82 M
1.02 B
163.36 M
1.13 B
566.77 M
11.72 M
N/A
644.39 M
1.66 B
Working Capital
77.67 M
374.34 M
396.85 M
280.82 M
258 M
79.69 M
N/A
7.92 M
264.19 M
965.29 M
Cash And Equivalents
36.56 M
63.38 M
98.67 M
383.85 M
58.49 M
122.72 M
60.62 M
59.41 K
183.39 M
580.97 M
Cash Per Share
2.75
3.89
2.44
5.74
0.72
3.6
9.75
0.01
3.74
3.54
Gross Profit
221.67 M
177.6 M
298.24 M
(62.55 M)
627.87 M
345.74 M
5.38 M
N/A
248.86 M
893.69 M
Day Typical Price
2.11
55.66
23.88
13.4
83.66
30.44
13.06
5.78
43.91
27.79
Accumulation Distribution
0.2
0.0289
0.0651
0.0401
0.0204
0.032
0.0219
0.0789
0.0326
0.0245
Market Facilitation Index
0.47
1.63
1.61
0.55
1.72
0.99
0.29
0.48
1.45
0.69
Daily Balance Of Power
0.0426
0.4663
0.2298
(0.65)
0.8547
0.4141
(0.55)
(0.10)
0.3241
(0.30)
Period Momentum Indicator
0.02
0.76
0.37
(0.36)
1.47
0.41
(0.16)
(0.05)
0.47
(0.21)
Rate Of Daily Change
1.01
1.01
1.02
0.97
1.02
1.01
0.99
0.99
1.01
0.99
Day Median Price
2.17
55.57
23.94
13.44
83.42
30.46
13.11
5.84
43.82
27.84
Price Action Indicator
(0.16)
0.67
0.01
(0.29)
1.45
0.16
(0.22)
(0.21)
0.51
(0.24)
Relative Strength Index
24.78
43.77
52.7
43.31
72.31
36.41
65.24
45.94
40.35
48.66
Coefficient Of Variation
(567.97)
(2,028)
614.61
(1,098)
430.0
(1,125)
952.24
(7,885)
(7,751)
(45,846)
Mean Deviation
3.94
1.85
2.0
1.66
0.9246
1.88
1.09
6.25
1.58
1.71
Jensen Alpha
(1.17)
(0.25)
0.2432
(0.22)
0.1998
(0.34)
0.1188
(0.02)
(0.09)
(0.18)
Total Risk Alpha
(2.08)
(0.43)
0.0744
(0.48)
0.1144
(0.53)
(0.05)
(1.35)
(0.37)
(0.31)
Sortino Ratio
N/A
N/A
0.1618
N/A
0.144
N/A
0.0405
N/A
N/A
N/A
Downside Variance
N/A
N/A
3.81
N/A
1.46
N/A
1.84
N/A
N/A
N/A
Standard Deviation
6.74
2.34
2.61
2.13
1.22
2.38
1.57
9.39
2.51
2.28
Kurtosis
16.35
0.3227
2.19
0.3671
0.5467
0.463
3.42
3.51
12.64
0.5641
Potential Upside
9.24
3.7
5.36
3.27
1.9
3.59
2.89
22.58
3.37
4.14
Treynor Ratio
3.76
(0.1)
0.2402
(1.14)
0.3702
(0.19)
0.431
0.1155
(0.1)
(0.01)
Maximum Drawdown
53.71
10.82
15.47
9.66
4.9
12.29
7.09
43.32
17.3
9.74
Variance
45.47
5.46
6.83
4.52
1.48
5.65
2.45
88.18
6.31
5.18
Market Risk Adjusted Performance
3.77
(0.09)
0.2502
(1.13)
0.3802
(0.18)
0.441
0.1255
(0.09)
9.0E-4
Risk Adjusted Performance
(0.13)
(0.03)
0.1312
(0.06)
0.1811
(0.06)
0.0852
(0.0005)
(0)
0.005
Skewness
(2.65)
0.3476
1.06
0.3297
0.1191
(0.38)
1.06
1.76
(2.41)
0.428
Semi Deviation
N/A
N/A
1.63
N/A
0.9128
N/A
1.04
N/A
N/A
N/A
Information Ratio
(0.19)
(0.1)
0.1208
(0.14)
0.1426
(0.13)
0.0351
(0.02)
(0.06)
(0.05)
Value At Risk
(8.24)
(3.75)
(2.45)
(3.25)
(1.76)
(4.47)
(1.82)
(10.93)
(3.61)
(3.59)
Expected Short fall
N/A
N/A
(2.32)
N/A
(1.02)
N/A
(1.35)
N/A
N/A
N/A
Downside Deviation
N/A
N/A
1.95
N/A
1.21
N/A
1.36
N/A
N/A
N/A
Semi Variance
N/A
N/A
2.66
N/A
0.8332
N/A
1.08
N/A
N/A
N/A

Eagle Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Eagle Pharmaceuticals Competition

Eagle Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Eagle Pharmaceuticals in relation to its competition. Eagle Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Eagle Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Eagle Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Eagle Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Eagle Pharmaceuticals position

In addition to having Eagle Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Online Gaming Thematic Idea Now

Online Gaming
Online Gaming Theme
Companies that are involved in the building and marketing of online gaming-related products. The Online Gaming theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Online Gaming Theme or any other thematic opportunities.
View All  Next Launch
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.

Other Consideration for investing in Eagle Pink Sheet

If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Global Correlations
Find global opportunities by holding instruments from different markets
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY